PA8807901A1 - Derivado de 17-(1'propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen - Google Patents

Derivado de 17-(1'propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen

Info

Publication number
PA8807901A1
PA8807901A1 PA20088807901A PA8807901A PA8807901A1 PA 8807901 A1 PA8807901 A1 PA 8807901A1 PA 20088807901 A PA20088807901 A PA 20088807901A PA 8807901 A PA8807901 A PA 8807901A PA 8807901 A1 PA8807901 A1 PA 8807901A1
Authority
PA
Panama
Prior art keywords
derivatives
oxidoestra
propenil
ona
derived
Prior art date
Application number
PA20088807901A
Other languages
English (en)
Inventor
Ulrich Klar
Joachim Kuhnke
Rolf Bohlmann
Jan Huebner
Sven Ring
Thomas Frenzel
Frederik Menges
Steffen Borden
Hans-Peter Muhn
Katja Prelle
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8807901(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PA8807901A1 publication Critical patent/PA8807901A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/001—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class spiro-linked
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

DERIVADOS DE 17-(1'-PROPENI)-17-3'-OXIDOESTRA-4-en--3-ona QUE TIENEN LA FÓRMULA QUÍMICA GENERAL I,EN LA CUAL Z,R4,R6a,R6b,R7,R15,R16a,R16b Y R18 TIENEN LOS VALORES QUE SE INDICAN EN LA REIVINDICACIÓN 1,ASÍ COMO SUS SOLVATOS,HIDRATOS Y SALES,INCLUYENDO TODOS LOS ESTEREOISÓMEROS DE ESTOS COMPUESTOS.USO DE ESTOS DERIVADOS PARA LA PREPARACIÓN DE UN MEDICAMENTO PARA LA CONTRACEPCIÓN ORAL Y PARA EL TRATAMIENTO DE TRASTORNOS PRE,PERI Y POSMENOPÁUSICOS Y A MEDICAMENTOS QUE CONTIENEN TALES DERIVADOS,PARTICULARMENTE EN LAS INDICACIONES MENCIONADAS.LOS DERIVADOS DE LA INVENCIÓN PRESENTAN UN EFECTO GESTAGÉNICO Y EN CASPS PREFERIDOS,ADICIONALMENTE UN EFECTO ANTIMINERALCORTICOIDE Y NEUTRO A LIGERAMENTE ANDROGÉNICO.
PA20088807901A 2007-12-29 2008-12-16 Derivado de 17-(1'propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen PA8807901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007063500A DE102007063500A1 (de) 2007-12-29 2007-12-29 17-(1'-Propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
PA8807901A1 true PA8807901A1 (es) 2009-07-23

Family

ID=40679349

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088807901A PA8807901A1 (es) 2007-12-29 2008-12-16 Derivado de 17-(1'propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen

Country Status (23)

Country Link
US (1) US9034856B2 (es)
EP (1) EP2238147B1 (es)
JP (1) JP5600069B2 (es)
KR (1) KR20100102190A (es)
CN (1) CN101918426A (es)
AR (1) AR069964A1 (es)
AU (1) AU2008342912A1 (es)
BR (1) BRPI0822068A2 (es)
CA (1) CA2710934C (es)
CL (1) CL2008003885A1 (es)
CR (1) CR11541A (es)
DE (1) DE102007063500A1 (es)
DO (1) DOP2010000201A (es)
EC (1) ECSP10010316A (es)
ES (1) ES2397985T3 (es)
IL (1) IL206381A0 (es)
MX (1) MX2010007269A (es)
PA (1) PA8807901A1 (es)
PE (1) PE20091185A1 (es)
TW (1) TW200940562A (es)
UY (1) UY31582A1 (es)
WO (1) WO2009083268A2 (es)
ZA (1) ZA201005397B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
CH559220A5 (es) 1970-03-06 1975-02-28 Ciba Geigy Ag
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
US3764596A (en) * 1971-06-22 1973-10-09 Sandoz Ag 17-dihydrofuranyl-substituted steroids
NL7701384A (nl) 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
FR2598421B1 (fr) * 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3702383A1 (de) * 1987-01-23 1988-08-04 Schering Ag 11ss-alkinylestrene und -estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE4232521A1 (de) 1992-09-22 1994-03-24 Schering Ag Gestagen wirksame 4,5;11,12-Estradiene, Verfahren zu ihrer Herstellung, diese Estradiene enthaltende Arzneimittel sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
DE102004063864A1 (de) 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
WO2009083268A3 (de) 2009-09-24
KR20100102190A (ko) 2010-09-20
ES2397985T3 (es) 2013-03-12
IL206381A0 (en) 2010-12-30
TW200940562A (en) 2009-10-01
JP2011507925A (ja) 2011-03-10
WO2009083268A2 (de) 2009-07-09
EP2238147A2 (de) 2010-10-13
CN101918426A (zh) 2010-12-15
CA2710934C (en) 2015-07-21
MX2010007269A (es) 2010-10-15
UY31582A1 (es) 2009-08-03
DOP2010000201A (es) 2010-07-15
US9034856B2 (en) 2015-05-19
CR11541A (es) 2010-08-05
EP2238147B1 (de) 2012-10-24
US20100317632A1 (en) 2010-12-16
JP5600069B2 (ja) 2014-10-01
PE20091185A1 (es) 2009-09-06
AU2008342912A1 (en) 2009-07-09
CA2710934A1 (en) 2009-07-09
ECSP10010316A (es) 2010-08-31
DE102007063500A1 (de) 2009-07-02
CL2008003885A1 (es) 2010-05-07
AR069964A1 (es) 2010-03-03
BRPI0822068A2 (pt) 2015-06-23
ZA201005397B (en) 2012-01-25

Similar Documents

Publication Publication Date Title
AR111425A2 (es) MODULADORES SELECTIVOS DE RECEPTORES DE ANDRÓGENOS (SARMs) Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN
UY30314A1 (es) Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
SV2004001690A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
UY30977A1 (es) Derivados de isoindolinas 4' -o-sustituidas. composiciones que las contienen y metodos para sus usos.
UY32978A (es) Derivados de la cromenona
CU23464B7 (es) (1,8)naftidirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
UY32083A (es) Aminoidanos sustituidos y sus análogos, y el uso farmacéuticos de los mismos
UY31918A (es) Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento
GT200500281A (es) Compuestos organicos.
AR061271A1 (es) Antagonistas de cgrp
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
UY29883A1 (es) Nuevos beta-agonistas que contienen indol, procedimientos para prepararlos, y su empleo como medicamentos
PA8720601A1 (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevenciòn de trastornos psicoticos
ECSP10010317A (es) Derivado 15,16-metilen-17-(1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene
ECSP099679A (es) Nuevos compuestos y sus usos 707
PA8807901A1 (es) Derivado de 17-(1'propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen
ECSP10010318A (es) Derivado de -lactona del esteroide del ácido 17-hidroxi-19-nor-21-carboxílico, su uso y el medicamento que lo contiene
CU20100138A7 (es) Derivados de 17-(1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen
CO6300840A2 (es) Derivado y-lactona de esteroide de acido 15, 16-metilen-17-hidroxi-19-nor-21-carboxilico su uso y medicamentos que contienen tal derivado
CU20100140A7 (es) Derivados de 15,16-metilen-17-(1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene
CU20100141A7 (es) Derivados de ganma-lactona del esteroide del ácido 17-hidroxi-19-nor-21-carboxílico, su uso y el medicamento que lo contiene
CU20100139A7 (es) Derivados de y-lactona de esteroide de ácido 15,16-metilen-17-hidroxi-19-nor-21-carboxílico, su uso y medicamentos que contienen tal derivado
TH104953A (th) อนุพันธ์ 17-(1'-โพรพีนิล)-17-3'-ออกซิโดเอสตรา-4-อีน-3-โอน, การใช้อนุพันธ์ดังกล่าว และผลิตภัณฑ์ยาที่มีอนุพันธ์
UY30434A1 (es) Derivados de quinazolina, su preparacion, su uso y medicamentos que los comprenden
UY27303A1 (es) Derivados de 4-aminopirimidina